Ube, Japan

Hidetoshi Sunamoto

This inventor holds 8 USPTO granted patents, plus 2 CIPO patents and 4 EPO patents. Top assignees: Ube Industries, Inc., Santen Pharmaceutical Co., Ltd., Daiichi Sankyo Company, Limited. Active years: 2009-2021.


% Patents Active = 37.5


 

Average Co-Inventor Count = 10.8

ph-index = 2

Forward Citations = 15(Granted Patents)


Location History:

  • Yamaguchi, JP (2015)
  • Ube, JP (2009 - 2021)

Company Filing History:


Years Active: 2009-2021

Loading Chart...
Loading Chart...
Loading Chart...
8 patents (USPTO):Explore Patents

Title: Hidetoshi Sunamoto: Innovator in Pharmaceutical Chemistry

Introduction

Hidetoshi Sunamoto is a prominent inventor based in Ube, Japan. He has made significant contributions to the field of pharmaceutical chemistry, holding a total of eight patents. His work focuses on innovative compounds that have potential applications in medicine.

Latest Patents

Among his latest patents is a substituted dihydropyrrolopyrazole derivative. This invention provides a compound represented by the general formula (Ia) or a pharmacologically acceptable salt thereof. In this formula, two R moieties each independently represent a Calkyl group or similar structures. Additionally, R, Rand Reach independently represent an optionally substituted linear or branched Calkyl group. This compound showcases the potential for new therapeutic agents.

Career Highlights

Hidetoshi Sunamoto has worked with notable companies such as Ube Industries, Inc. and Santen Pharmaceutical Co., Ltd. His experience in these organizations has allowed him to develop and refine his innovative ideas in pharmaceutical research.

Collaborations

Some of his notable coworkers include Masahiko Hagihara and Ken-ichi Komori. Their collaboration has likely contributed to the advancement of their shared projects and innovations.

Conclusion

Hidetoshi Sunamoto is a distinguished inventor whose work in pharmaceutical chemistry has led to multiple patents and significant advancements in the field. His contributions continue to influence the development of new therapeutic compounds.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…